-
Capital, M&A & Industry Strategy1 month agoSleep deals cluster in narcolepsy and sleep apnea
BIOCENTURY | DATA BYTESLEEP DEALS CLUSTER IN NARCOLEPSY AND SLEEP APNEANarcolepsy drives the biggest transactions, while venture financing across the sleep field remains sparse
-
Capital, M&A & Industry Strategy1 month agoNovartis to pay $125M for blood-brain barrier crossing platform
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class”...
-
Capital, M&A & Industry Strategy2 months agoGilead and PAHO agree to expedite lenacapavir access for HIV prevention
The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries,...
-
Capital, M&A & Industry Strategy2 months agoEli Lilly and QurCan sign genetic medicine deal
The companies intend to work together on several research programmes focused on QurCan’s Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development. QurCan uses its...
-
Capital, M&A & Industry Strategy2 months agoNovartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets...
-
Capital, M&A & Industry Strategy2 months agoFor many, the retirement goal posts are shifting
Biopharma professionals are among those delaying retirement, with 52% expecting to leave the workforce later than originally planned, according to a BioSpace LinkedIn poll. A career...
-
Capital, M&A & Industry Strategy2 months agoFDA clears first generic radioligand drug; Sionna turns to layoffs
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed...
-
Capital, M&A & Industry Strategy2 months agoElectra sets terms for IPO, hoping to raise up to $347m
Electra Therapeutics has moved ahead with plans for an IPO, seeking to raise funds for its drug for the rare and life-threatening disease sHLH.
-
Capital, M&A & Industry Strategy2 months agoCheplapharm to take over 20 medicines and three sites from Sanofi
Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began...
-
Capital, M&A & Industry Strategy2 months ago
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
Sionna Therapeutics is laying off almost half its workforce as the company recovers from the failure of its closely watched cystic fibrosis add-on program.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
